Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by K. Lehnhoff
Elara: A Phase 2 Trial Investigating the Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory/Relapsed Follicular Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Efficacy and Safety of Obinutuzumab + Lenalidomide + Atezolizumab in Patients With Relapsed or Refractory Follicular Lymphoma: Primary Analysis of a Phase 1b/2 Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Bianca: A Phase 2 Study of the Safety and Efficacy of Tisagenlecleucel in Pediatric Patients With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma
Cancer
Cancer Research
Oncology
Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Investigating Safety and Preliminary Efficacy of Afm13 Plus Pembrolizumab in Patients With Relapsed/Refractory Hodgkin Lymphoma After Brentuximab Vedotin Failure
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Umbralisib Monotherapy Demonstrates Efficacy and Safety in Patients With Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Registration Directed Phase 2 Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Intravenous Immunoglobulin Therapy Use in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated With Tisagenlecleucel in the Juliet Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Interim Update From a Phase 2 Multicenter Study of Tazemetostat, an Ezh2 Inhibitor, in Patients With Relapsed or Refractory Follicular Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Safety and Activity of Ibrutinib in Combination With Durvalumab in Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B‐cell Lymphoma
American Journal of Hematology
Hematology
